Recent Price Movement and Market Context
On the day in question, Samrat Pharmachem’s stock recorded an intraday low of Rs.206, down 3.47% from the previous close. Despite touching an intraday high of Rs.218.1, the stock closed near its low point, underscoring selling pressure. This decline contributed to a three-day consecutive fall, resulting in a cumulative loss of 8.63% over this period. The stock’s performance notably lagged behind the Pharmaceuticals & Biotechnology sector, which outperformed by 3.74% on the same day.
Technical indicators reveal that the stock is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This broad-based weakness in technicals signals a sustained bearish trend. In contrast, the Sensex, while also experiencing a decline of 0.87% on the day, remains above its 200-day moving average despite trading below its 50-day average. The Sensex has been on a three-week losing streak, shedding 5.01% in that timeframe, highlighting a challenging market environment.
Long-Term Performance and Valuation Concerns
Over the past year, Samrat Pharmachem’s stock has delivered a negative return of 41.96%, starkly underperforming the Sensex’s positive 7.42% gain. The stock’s 52-week high stood at Rs.425, indicating a near 52% decline from its peak. This persistent underperformance extends beyond the last year, with the company lagging behind the BSE500 index in each of the previous three annual periods.
From a valuation standpoint, the company’s Price to Book Value ratio stands at 0.9, which is considered expensive relative to its peers’ historical averages. Despite this premium, the company’s return on equity (ROE) remains low at 2.2%, reflecting limited profitability relative to shareholder equity. This disparity between valuation and profitability metrics contributes to the cautious market sentiment surrounding the stock.
This week's revealed pick, a Large Cap from Public Banks with TARGET PRICE, is already showing movement! Get the complete analysis before it's too late.
- - Target price included
- - Early movement detected
- - Complete analysis ready
Financial Performance Highlights
Samrat Pharmachem’s recent financial results have reflected subdued performance. The company reported flat results in the quarter ending September 2025, with operating cash flow for the year registering a low of Rs. -10.09 crores. Quarterly PBDIT (Profit Before Depreciation, Interest and Taxes) was also at a low, standing at Rs. -0.36 crores. Operating profit as a percentage of net sales for the quarter was negative at -0.46%, indicating that the company’s core business activities are not generating positive returns.
Profitability has deteriorated significantly over the past year, with profits falling by 75.9%. This decline has contributed to the stock’s weak fundamental strength, which is reflected in its current Mojo Score of 16.0 and a Mojo Grade of Strong Sell, downgraded from Sell on 19 Aug 2025. The company’s market capitalisation grade is rated at 4, indicating a relatively small market cap within its sector.
Shareholding and Sectoral Position
The majority shareholding in Samrat Pharmachem remains with the promoters, maintaining a concentrated ownership structure. The company operates within the Pharmaceuticals & Biotechnology sector, which has experienced mixed performance amid broader market volatility. Despite sectoral headwinds, Samrat Pharmachem’s underperformance relative to its peers and the benchmark indices has been pronounced.
Samrat Pharmachem Ltd or something better? Our SwitchER feature analyzes this micro-cap Pharmaceuticals & Biotechnology stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Summary of Key Metrics
To summarise, Samrat Pharmachem Ltd’s stock has reached a new 52-week low of Rs.206, reflecting ongoing challenges in both market sentiment and company fundamentals. The stock’s three-day losing streak and underperformance relative to the sector and Sensex highlight persistent downward momentum. Financial indicators such as negative operating cash flow, declining profits, and low operating margins underscore the pressures on the company’s earnings capacity.
Valuation metrics suggest the stock is trading at a premium despite limited profitability, while the downgrade to a Strong Sell grade by MarketsMOJO further emphasises the cautious outlook. The company’s concentrated promoter ownership and its position within the Pharmaceuticals & Biotechnology sector provide additional context to its current market standing.
Market Environment and Broader Trends
The broader market environment has been challenging, with the Sensex falling by 331.35 points to 81,463.30 on the day, continuing a three-week decline. The index’s movement below its 50-day moving average, albeit above the 200-day average, indicates some near-term weakness but longer-term resilience. Against this backdrop, Samrat Pharmachem’s sharper decline and sustained underperformance highlight company-specific factors contributing to its share price erosion.
Conclusion
Samrat Pharmachem Ltd’s fall to a 52-week low of Rs.206 on 21 Jan 2026 marks a significant point in its recent market journey. The stock’s performance reflects a combination of subdued financial results, valuation concerns, and broader market pressures. While the company remains under close observation, the current data points to a continuation of the challenging environment that has characterised its recent performance.
Unlock special upgrade rates for a limited period. Start Saving Now →
